Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
search results for:
dealforma
Search
After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?
7 years ago
Pharma
By the numbers: Top M&A deals, VC investments and pacts point to a growing hunger for gene therapy deals
7 years ago
Pharma
Cell/Gene Tx
Roche joins the M&A game, buying gene therapy pioneer Spark for $4.3B
7 years ago
Deals
Cell/Gene Tx
The $100M biotech club: Who's in, and what’s it take to join the top-performing group of biopharmas?
7 years ago
Pharma
The high rollers: The top 20 blockbuster biopharma deals of the past decade
7 years ago
Pharma
Top 20 biotech deals: 2019 dealmaking gets off to a roaring start, building on a record amount for '18
7 years ago
Pharma
By the numbers for 2018: The top 100 venture players in biotech — and who's been paying the piper in cancer R&D?
7 years ago
Financing
Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management
7 years ago
Financing
Pharma
Celgene's top 20 upfront hits: Just how generous was Celgene in dealmaking? Let's review the records
7 years ago
Pharma
The high-roller club in biopharma: Who’s paying top-dollar for upfronts? And who are the busiest players at the ...
7 years ago
R&D
Pharma
First page
Previous page
4
5
6
7
latest
Most read
Biopharma's 20 highest-paid CEOs of 2024 with $20M+ paydays
4 days ago
People
Pharma
Biopharma’s highest-paid CEOs; John Carroll’s Q2 analysis; Merck to buy Verona Pharma for $10B; and more
22 hours ago
Weekly
Karyopharm cuts 20% of staff as it looks at 'strategic alternatives' or raising cash
Yesterday
Financing
European regulators lift restriction on Valneva’s chikungunya vaccine
Yesterday
Pharma
FDA+
Novartis dealt a blow in patent fight to block Entresto generics
Yesterday
Pharma
Law
see latest stream